BMS’s Triple Regimen Receives European Commission Approval for Relapse/Refractory Multiple Myeloma

Shots:

• The approval is based on P-II ELOQUENT-3 study assessing Empliciti (elotuzumab) + pomalidomide and low-dose dexamethasone (EPd) vs pomalidomide and low-dose dexamethasone (Pd) in 117 patients with r/r MM prior treated with 2L+ therapies including lenalidomide and a proteasome inhibitor (PI) with disease progression on the last therapy
• The P-III ELOQUENT-3 study results: The EPd doubled PFS and ORR compared to Pd alone i.e, PFS (10.25 vs 4.67mos.) indicating 46% reduction in disease progression; ORR (53.3% vs 26.3%); % of patients alive (67% vs 51%)
• Empliciti is an immunostimulatory Ab works on a dual mechanism, activating the immune system through NK cells via the SLAMF7 pathway and targets SLAMF7 on myeloma cells, tagging NK cells mediated destruction via antibody-dependent cellular toxicity

Click here to­ read full press release/ article | Ref: BMS | Image: WSJ